Current diagnostic approaches in tumor-induced bone disease

Journal of B.U.ON.

Volumn 12, Issue 4, 2007, Pages 493-504

  Sergieva, Sonia ^a   Kirova, G ^b   Dudov, A ^a  

^a Sofia Cancer Centre   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Bone metastases; Bone scintigraphy; Computed tomography; Magnetic resonance imaging

Indexed keywords

MEDRONATE TECHNETIUM TC 99M;

ARTICLE; BOLUS INJECTION; BONE DISEASE; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINERAL METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGIC FRACTURE; PATIENT MONITORING; RADIOISOTOPE DISTRIBUTION; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SPINAL PAIN; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

BONE NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 38349166704     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mundy GR. Mechanism of bone metastases. Cancer 1997; 80 (Suppl): 1546-1556.
2. Coleman R. Incidence and distribution of bone metastases. In: Diel I, Kaufmann M, Basrert G (Eds): Metastatic bone disease. Springer Verlag, 1994, pp 20-21.
3. Rybak LD, Rosenthal LM. Radiological imaging for the diagnosis of bone metastases. Quart J Nucl Med 2001; 45: 53-64.
4. Rogers LF. Secondary malignancies of bone. In: Juhl JH, Crummy AB (Eds): Paul and Juhl's Essential of Radiological Imaging (6th edn). Philadelphia, JB Lippincott Co, 1993, pp 164-165.
5. Trail ZC, Talbot D, Golging S, Gleeson FV. Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol 1999; 54: 448-451.
6. Ripamonti C, Fulfaro F. Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. QJNM 2001; 45: 65-78.
7. Brown H, Healy J. Metastatic cancer to the bone. Ch 52: Treatment of metastatic cancer. In: De Vita V, Hellman S, Rosenberg S (Eds): Cancer: Principles and Practice of Oncology (6th Edn). Philadelphia, JB Lippincott Co, 2001, pp 562-587.
8. Cheer SM, Npble S. Zoledronic acid. Drugs 2001; 61: 799-805.
9. Porter A, Fontanesi J. Palliative irradiation for bone metastasis: a new paradigm. Int J Radiat Oncol Biol Phys 1994; 29: 1199-1206.
10. Silberstein VJ. Systemic radiopharmaceutical therapy for painful osteoblastic metastases. Semin Radiat Oncol 2000; 10: 2934-2939.
11. Piffanelli A, Dafermou A, Giganti M et al. Radionuclide therapy for painful bone metastases. Q J Nucl Med 2001; 45: 100-107.
12. Pauwels EKJ, Stokkel MPM. Radiopharmaceuticals for bone lesions. Q J Nucl Med 2001; 45: 18-26.
13. Fettich J, Padhy A, Nair N et al. Comparative clinical efficacy and safety of Phosphorus-32 and Strontium-89 in the palliative treatment of metastatic bone pain: results of an IAEA Coordinated Research Project. Word J Nucl Med 2003; 2: 226-231.
14. Riccabona G. Nuclear medicine in diagnosis and therapy of bone and joint diseases. Nucl Med Rev 1999; 2: 42-52.
15. Jones A, Francis M, Davis M. Bone scanning: radionuclide reaction mechanisms. Semin Nucl Med 1976; 6: 3-18.
16. Solav SV, Shingate S. Profile of osteolytic lesions on bone scan. WJNM 2004; 3 (Suppl 1): S56 (abstr).
17. Solav SV. Lack of hypervascularity on three phase bone scan: Osteoid osteoma revisited. WJNM 2006; 5: 18-31.
18. Smith FW, Gilday DL. Scintigraphic appearances of osteoid osteoma. Radiology 1980; 137: 191-195.
19. Braunstein EM, Kuhns LR. CT demonstration of spinal metastases. Spine 1983; 8: 912-915.
20. Jonsson B, Petrn-Mallmin M, Anderson I et al. Pathological and radiographic findings in spinal breast cancer metastases. Acta Radiol 1991; 23: 219-223.
21. Libshitz HI, Hortobagyi GN. Radiographic evaluation of therapeutic response in bony metastases of breast cancer. Skeletal Radiol 1981; 7: 323-328.
22. Vandemark RM, Shpall EJ, Affronti ML. Bone metastases from breast cancer. Value of CT bine windows. J Computed Assist Tomogr 1992; 16: 608-614.
23. Lauenstein TC, Freudenberg LS, Goehde SC et al. Wholebody MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 2002; 12: 2091-2099.
24. Flickinger F, Salahattin S. Bone marrow MRI: techniques and accuracy for detecting breast cancer metastases. Magn Reson Imaging 1994; 12: 829-835.
25. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34: 252-259.
26. Jones KM, Schwartz RB, Mantello MT et al. Fast spin-echo MR in the detection of vertebral metastases: comparison of three sequences. Am J Neuroradiol 1994; 15: 401-407.
27. Freedman GM, Negendank WG, Hudes GR. Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer. Urology 1999; 54: 118-123.
28. Tamada T, Nagai K, Iizuka M et al. Comparison of whole-body MR imaging and bone scintigraphy in the detection of bone metastases from breast cancer. Nippon Acta Radiol 2000; 60: 249-254.
29. Frank JA, Ling A, Patronas NJ et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. Am J Roentgenol 1990; 155: 1043-1048.
30. Neumann K, Hosten N, Venz S. Screening for skeletal metastases of the spine and pelvis: gradient echo opposed-phase MRI compared with bone scintigraphy. Eur Radiol 1995; 5: 276-284.
31. Cheon GJ, Chung JK, Kim YK et al. Comparison of whole body F-18 FDG PET and Tc-99m MDP bone scan for the assessment of metastatic bone lesions. WJNM 2003; 2: 18-29.
32. 18F-fuorodeoxyglucose positron emission tomography. Q J Nucl Med 2001; 45: 47-52.
33. Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23: 693-697.
34. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34: 252-259.
35. Cook GJ, Houston S, Rubens R et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379.